Dasatinib

Dasatinib is an orally active, short-acting tyrosine kinase inhibitor. It potently blocks the BCR-ABL fusion protein and Src-family kinases and also acts on c-KIT, the PDGF receptors, and ephrin receptor kinases ^[1]. As a second-generation agent, it inhibits BCR-ABL considerably more strongly than the first-generation drug imatinib, which is central to its clinical role ^[1].

The drug was developed by Bristol-Myers Squibb, is named after the researcher Jagabandhu Das, and was approved by the U.S. Food and Drug Administration in June 2006, with European approval later the same year. It is marketed as Sprycel ^[1].

Chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia are driven by a constantly active BCR-ABL kinase produced by the Philadelphia chromosome. Dasatinib is used across all phases of chronic myeloid leukemia and in this form of acute lymphoblastic leukemia, and it remains effective in many cases that are resistant to or intolerant of imatinib, although it does not overcome the T315I mutation; used first-line it produces early, deep molecular responses that correlate with better long-term outcomes ^[1].

Separately, dasatinib has become a tool in the study of aging. Combined with the plant flavonoid quercetin, it functions as a senolytic, selectively eliminating senescent cells by briefly disabling the pro-survival pathways those cells rely on ^[3][4]. In a first-in-human pilot study in idiopathic pulmonary fibrosis, intermittent dasatinib plus quercetin proved feasible and was associated with improved physical function ^[3], and a small study in people with diabetic kidney disease found that the combination measurably reduced senescent-cell burden in human tissue ^[4]. These remain early, exploratory findings rather than approved uses.

The main side effects reflect its potency and include low blood cell counts, fluid accumulation around the lungs, and, rarely, pulmonary arterial hypertension ^[1]. Its absorption depends heavily on stomach acidity, and because it is cleared largely by cytochrome P450 enzymes, it is prone to interactions with acid-reducing agents and other drugs ^[2]. Dasatinib is a prescription-only medicine supplied as oral tablets, and expiry of several patents has opened the way to generic versions.

This is a Serious Drug with significant risks: fluid retention, pleural effusion, bleeding, low blood counts, and cardiac effects among them. It interacts with CYP3A4 drugs and requires medical monitoring. Its senolytic use in longevity is experimental and should only occur within trials or under a physician; self-dosing is genuinely dangerous.

Dasatinib is a substrate for CYP3A4, the major hepatic enzyme responsible for its metabolism. Strong CYP3A4 inhibitors require dasatinib dose reductions of 50-80%, while CYP3A4 inducers may require 2.3-3.1-fold dose increases to maintain dasatinib exposure ^[5]. Additionally, dasatinib is transported by efflux pumps P-glycoprotein and BCRP; compounds that inhibit these transporters can increase dasatinib bioavailability. Interactions poorly studied include co-administration with moderate CYP3A4 inhibitors, herbal products beyond thymoquinone, and the effect of acid-reducing agents at lower doses.

Checking a whole stack? Run it through interactions + stacks.